Novel Therapies in Lung Cancer Management: An Update on the Role of Topotecan

Based on Proceedings from the 9th World Conference on Lung Cancer, Tokyo, September 2000

Guest Editor
Joan H. Schiller, Madison, Wisc.
The ideas and opinions expressed in Oncology do not necessarily reflect those of the Editor, the Publisher, or GlaxoSmithKline. Publication of an advertisement or other product mention in Oncology should not be construed as an endorsement of the product or the manufacturer’s claims. Readers are encouraged to contact the manufacturer with any questions about the features or limitations of the products mentioned. Neither GlaxoSmithKline nor the Publisher assumes any responsibility for any injury and/or damage to persons or property arising out of or related to any use of the material contained in this periodical. The reader is advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other healthcare professional, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient.
Contents

Foreword

1 Novel Therapies in Lung Cancer Management. An Update on the Role of Topotecan
Schiller, J.H. (Madison, Wisc.)

3 Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
Schiller, J.H. (Madison, Wisc.)

14 New Advances in Lung Cancer Chemotherapy: Topotecan and the Role of Topoisomerase I Inhibitors
Huang, C.H.; Treat, J. (Philadelphia, Pa.)

25 A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer
O’Neill, P.; Clark, P.I.; Smith, D.; Marshall, E.; Hannigan, K. (Bebington); Ross, G. (Welwyn Garden City)

30 Feasibility of Oral Topotecan Plus Intravenous Paclitaxel in Advanced Non-Small-Cell Lung Cancer
Eckardt, J.R. (St. Louis, Mo.)

35 Is Cisplatin Required for the Treatment of Non-Small-Cell Lung Cancer? Experience and Preliminary Results of a Phase I/II Trial with Topotecan and Vinorelbine

42 Feasibility of Oral Topotecan in Previously Untreated Patients with Small-Cell Lung Cancer Ineligible for Standard Therapy
Eckardt, J.R. (St. Louis, Mo.)

47 Preliminary Results of Combined Therapy with Topotecan and Carboplatin in Advanced Non-Small-Cell Lung Cancer
Pujol, J.L. (Montpellier); von Pawel, J. (Munich); Tumolo, S. (Aviano); Martoni, A. (Bologna); Hearn, S.; Fields, S.Z.; Ross, G. (Brentford)

55 Future Role of Topotecan in the Treatment of Lung Cancer
Schiller, J.H. (Madison, Wisc.)

60 Author Index and Subject Index